| Released | Contributor | Author | Title | Pages | Price |
| 27-Dec-2009 | Wright Reports |
N/A
| Wright Industry Averages: Health, Medicine and Pharmaceuticals (North America) | 103 |
$169 |
| 27-Dec-2009 | Wright Reports |
N/A
| Wright Industry Averages: Automotive (United States) | 61 |
$169 |
| 27-Dec-2009 | Wright Reports |
N/A
| Wright Industry Averages: Health, Medicine and Pharmaceuticals (Global) | 148 |
$169 |
| 27-Dec-2009 | Wright Reports |
N/A
| Wright Industry Averages: Automotive (North America) | 65 |
$169 |
| 27-Dec-2009 | Wright Reports |
N/A
| Wright Industry Averages: Health, Medicine and Pharmaceuticals (United States) | 100 |
$169 |
| 27-Dec-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (VRX). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (VRX). | 5 |
$18 |
| 26-Dec-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 26-Dec-2009 | PriceTarget Research, Inc. |
N/A
| S&P MidCap Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 25 new Laggards. | 65 |
$40 |
| 25-Dec-2009 | Pechala's Reports | Frantisek Pechala | VALEANT PHARMACEUTICALS INTL (VRX=US) 12-months forecast | 1 |
$15 |
| 25-Dec-2009 | Reuters Investment Profile |
N/A
| Valeant Pharmaceuticals International: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 12 |
$20 |
0.51% Nasdaq 
Research Reports
